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ABSTRACT 
 Background and purpose: Pulmonary arterial hypertension (PAH) is an 
incurable, incapacitating disorder resulting from increased pulmonary vascular 
resistance, pulmonary arterial remodeling and right ventricular failure. In pre-clinical 
models, combination of a phosphodiesterase 5 inhibitor (PDE5i) with a neprilysin 
inhibitor augments natriuretic peptide bioactivity, promotes cyclic GMP signaling, and 
reverses the structural and hemodynamic deficits that characterize PAH. Herein, we 
conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy 
and safety of repurposing the neprilysin inhibitor, racecadotril, in PAH. 
 Experimental approach: 21 PAH patients stable on PDE5i therapy were 
recruited. Acute hemodynamic and biochemical changes following a single dose of 
racecadotril or matching placebo were determined; this was followed by a 14 day 
safety and efficacy evaluation. The primary endpoint in both steps was circulating atrial 
natriuretic peptide (ANP) concentration (Δmax), with secondary outcomes including 
pulmonary and systemic hemodynamics plus mechanistic biomarkers. 
Key results: Acute administration of racecadotril (100mg) resulted in a 79% 
(95%CI, +6,+203) increase in the plasma ANP concentration and a 106% (+28,+229) 
increase in plasma cyclic GMP levels, with a concomitant 14% (-24,-3) fall in 
pulmonary vascular resistance. Racecadotril (100mg; tid) treatment for 14 days 
resulted in a 19% (-18,+72) rise in plasma ANP concentration. Neither acute (-16%, 
-28,+1) nor chronic (-4%, -21,+16) administration of racecadotril resulted in a 
significant drop in MABP or any serious adverse effects. 
 Conclusions and implications: This Phase IIa evaluation provides proof-of-
principle evidence that neprilysin inhibitors may have therapeutic utility in PAH and 
warrants a larger-scale prospective trial. 
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BULLET POINT SUMMARY 
What is already known 
 Drugs that elevate cyclic GMP (i.e. PDE5 inhibitors) have proven efficacy in 
pulmonary arterial hypertension (PAH) 
 Neprilysin inhibitors augment natriuretic peptide-driven cyclic GMP signalling and 
are licensed for use in heart failure 
 
What this study adds 
 Combining PDE5 and neprilysin inhibitors produces additive beneficial 
haemodynamic effects in PAH patients 
 
Clinical significance 
 These data support a larger prospective trial evaluating the repurposing of 
neprilysin inhibitors for PAH 
 
 
NON-STANDARD ABBREVIATIONS 
6MWD 6 minute walk distance 
ACE Angiotensin converting enzyme 
ALT Alanine transaminase 
ANP Atrial natriuretic peptide 
APTT Activated partial thromboplastin time 
AST Aspartate transaminase 
BNP Brain natriuretic peptide 
cGMP Cyclic guanosine-3’,5’-monophosphate 
CHD Congenital heart disease 
CNP C-type natriuretic peptide 
CO Cardiac output 
CTD Connective tissue disease 
eGFR Estimated glomerular filtration rate 
ERA Endothelin receptor antagonist 
ET-1  Endothelin-1 
GC-1 NO-sensitive guanylyl cyclase α1β1 isoform 
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GC-2 NO-sensitive guanylyl cyclase α2β1 isoform 
GC-A Natriuretic peptide-sensitive guanylyl cyclase-A 
Hb Haemoglobin 
HR Heart rate 
IDMC Independent data monitoring committee 
IMP Investigational medicinal product 
LA Left atrium 
LVEF Left ventricular ejection fraction 
MABP Mean arterial blood pressure 
mPAP Mean pulmonary artery pressure 
NEP Neprilysin/neutral endopeptidase 
NOx [NO2-] + [NO3-] 
PAH Pulmonary arterial hypertension 
PCWP Pulmonary capillary wedge pressure 
PDE5i Phosphodiesterase 5 inhibitor 
PH Pulmonary hypertension 
PT Prothrombin time 
PVR Pulmonary vascular resistance 
RA Right atrium 
RBC Red blood cell count 
RHC Right heart catheterization 
RV Right ventricle 
RVH Right ventricular hypertrophy 
SV Stroke volume 
TAPSE Tricuspid annular plane systolic excursion 
TRV Tricuspid regurgitant velocity 
TSC Trial steering committee 
ULN Upper limit of normal 
WBC White blood cell count 
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INTRODUCTION 
Pulmonary hypertension (PH) is progressive, debilitating disorder with high 
associated morbidity and mortality. It is characterized by increased pulmonary 
vascular resistance (PVR) and a degenerative remodeling of the pulmonary arterial 
tree, leading initially to right ventricular (RV) failure and death. A cure remains elusive 
and contemporary strategies to improve therapy have focused on developing drug 
combinations that synergize in the pulmonary circulation, improving hemodynamics 
and reversing structural remodeling (Ghofrani et al., 2002; Hoeper, Faulenbach, 
Golpon, Winkler, Welte & Niedermeyer, 2004; Humbert et al., 2004). 
Targeting cyclic GMP (cGMP) is effective in treating PH, exemplified by the 
clinical use of phosphodiesterase 5 inhibitors (PDE5i) (Galie et al., 2005) and soluble 
guanylyl cyclase (NO-sensitive GC-1 & GC-2; ‘sGC’) stimulators (Ghofrani et al., 
2013). However, these approaches only slow disease progression rather than offering 
resolution. Pre-clinical studies exploring cGMP signaling in the pulmonary circulation 
have provided compelling evidence to support atrial natriuretic peptide (ANP) and/or 
brain natriuretic peptide (BNP) -driven cGMP production in optimizing cGMP-based 
therapy founded on PDE inhibition, both in terms of efficacy and (pulmonary) 
selectivity. For example, the beneficial effects of PDE5i in experimental models of 
chronic hypoxia-induced PH are blunted in animals lacking GC-A (the cognate 
receptor for ANP and BNP) (Zhao, Mason, Strange, Walker & Wilkins, 2003); a 
similarly exacerbated phenotype in observed in GC-A-/- animals with bleomycin-
triggered pulmonary fibrosis and secondary PH, with an associated loss of efficacy of 
PDE5i (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014). Furthermore, 
infusion of natriuretic peptides in the presence of the PDE5i sildenafil, synergistically 
reduces pulmonary artery pressure in hypoxia-induced PH (Preston, Hill, 
Gambardella, Warburton & Klinger, 2004); a similar interaction has been reported 
between urodilatin (a renal-specific ANP variant) and the PDE5i dipyridamole 
(Schermuly et al., 2001). Similarly, infusion of monoclonal antibodies neutralizing ANP 
stimulates the development of PH in response to hypoxia (Raffestin et al., 1992), while 
exogenously administered or adenovirus-mediated natriuretic peptide 
supplementation protects against PH and the accompanying RVH (Jin, Yang, Chen, 
Jackson & Oparil, 1988; Klinger et al., 1993; Louzier et al., 2001). Such findings 
suggest that the mechanism of pulmonary selectivity of PDE5i depends on the 
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bioactivity of natriuretic peptides and, additionally, that in PH release of natriuretic 
peptides represents a cytoprotective mechanism that slows disease progression. 
One potential mechanism that might be utilized pharmacologically in PH to 
promote this protective role of natriuretic peptides is to inhibit the enzyme neprilysin 
(or neutral endopeptidase, NEP). NEP is a membrane bound zinc metallopeptidase 
responsible for the metabolism and inactivation of an array of vasodilator (e.g. 
natriuretic peptides, adrenomedullin, vasoactive intestinal peptide) and 
vasoconstrictor (e.g. Angiotensin II, Endothelin-1 (ET-1)) peptides (Erdos & Skidgel, 
1989; Kenny & Stephenson, 1988). Indeed, pre-clinical evidence indicates that NEP-/- 
mice are less susceptible to hypoxia-induced pulmonary edema (Irwin, Patot, Tucker 
& Bowen, 2005) and that inhibition of NEP attenuates hypoxia-induced PH by 
potentiating the action of natriuretic peptides (Klinger, Petit, Warburton, Wrenn, Arnal 
& Hill, 1993; Thompson, Sheedy & Morice, 1994; Winter, Zhao, Krausz & Hughes, 
1991). These observations fit with the up-regulation of NEP in the pulmonary 
circulation during acute lung injury and heart failure (Abassi, Kotob, Golomb, Pieruzzi 
& Keiser, 1995; Hashimoto, Amaya, Oh-Hashi, Kiuchi & Hashimoto, 2010). 
We exploited this ‘natriuretic peptide-centric’ approach to evaluate the 
therapeutic potential of a PDE5i and NEPi combination in animal models of PH (Baliga, 
Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014; Baliga et al., 2008). Our data 
showed that this dual therapy is superior to either drug alone in hypoxia-induced PH 
and PH secondary to pulmonary fibrosis. This held true for both hemodynamic (e.g. 
pulmonary artery pressure) and structural (e.g. right ventricular hypertrophy, 
pulmonary arterial remodeling) indices; importantly however, combination therapy did 
not significantly affect systemic blood pressure, confirming selective targeting of the 
pulmonary vasculature (Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 
2014; Baliga et al., 2008). Thus, by combining a PDE5i and a NEPi it is possible to 
harness further the beneficial effects of natriuretic peptide-cGMP signaling, thereby 
optimizing pulmonary efficacy and selectivity. 
A clear advantage of evaluating this novel PDE5i/NEPi combination in PH 
patients is the availability of existing licensed medications; the PDE5i sildenafil and 
tadalafil are prescribed for the treatment of PAH and the NEPi, racecadotril, is also 
licensed for use in secretory diarrhea. In accord, this report describes a randomized, 
double-blind, placebo controlled trial to assess the safety and efficacy of repurposing 
racecadotril in PAH patients stable on PDE5i therapy. 
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METHODS 
Study design and participants 
This study was a single-center, double-blind, phase IIa, randomized, placebo-
controlled trial conducted in two stages (with planned interim and final analyses), to 
determine whether administration of the NEPi, racecadotril, to patients with pulmonary 
arterial hypertension (PAH; WHO Group 1) on PDE5i therapy, increases plasma [ANP] 
and favorably alters pulmonary hemodynamics without affecting mean arterial blood 
pressure (MABP). The trial was approved by a local independent research ethics 
committee (NRES Committee London – Westminster; ref: 13/LO/0387), the Medicines 
and Healthcare Products Regulatory Agency (ref: 20363/0320/001-0003), 
documented in approved registries (EudraCT#2012-003921-13), and conducted in 
accordance with the Declaration of Helsinki (1996) and the principles of the 
International Conference on Harmonization-Good Clinical Practice guidelines. Trial 
management was undertaken by the UCL Comprehensive Clinical Trials Unit (CCTU) 
and an Independent Trial Steering Committee (TSC) and Independent Data Monitoring 
Committee (IDMC) provided trial oversight. Eligible patients at the Royal Free London 
NHS Foundation Trust who gave written informed consent were included in the trial. 
 
Step 1 
After consenting, patients considered for Step 1 of the trial underwent right 
heart catheterization (RHC) as routine care. Patients who met the inclusion criteria 
were randomized to receive a single dose of racecadotril (100mg; p.o.) or matching 
placebo (concurrently with their existing PDE5i therapy). The access sheath to the 
catheter was maintained in position so that pulmonary and systemic hemodynamic 
measurements could be recorded at 1.5 and 2 h following administration of 
racecadotril or placebo, after which it was removed. Venous blood samples were also 
collected at baseline, 0, 1, 2, 3 & 6 h following administration of racecadotril or placebo 
for the assessment of biochemical endpoints.  
 
Step 2 
Patients were randomized to receive racecadotril (100mg, tid; p.o.) or matching 
placebo for 14 days in addition to (and concomitantly with) their current PH-directed 
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therapy. Systemic blood pressure measurements and venous blood samples were 
taken at baseline (day 0) and day 14. A telephone conversation at day 7 was 
undertaken to assess the occurrence of any adverse events. 
 
Endpoints 
Step 1 
The primary endpoint was the maximum change (Δmax) in plasma [ANP]. 
Secondary endpoints comprised a range of pulmonary & systemic hemodynamic 
indices: Δmax mean pulmonary artery pressure (mPAP), Δmax pulmonary vascular 
resistance (PVR), Δmax pulmonary capillary wedge pressure (PCWP), Δmax mean 
arterial blood pressure (MABP), Δmax plasma [BNP], Δmax plasma [NT-proBNP], Δmax 
plasma [C-type natriuretic peptide (CNP)], Δmax plasma [ET-1], Δmax plasma [cGMP], 
Δmax plasma [NOx] 
 
Step 2 
The primary co-endpoints were safety (adverse effects; assessed for 
seriousness, severity and causality by on-site clinicians and reported to the IDMC) 
and Δmax plasma [ANP]. 
Secondary endpoints comprised a range of systemic hemodynamic indices: 
Δmax MABP, Δmax plasma [BNP], Δmax plasma [NT-proBNP], Δmax plasma [CNP], Δmax 
plasma [ET-1], Δmax plasma [cGMP], Δmax plasma [NOx] 
 
Study drug 
The NEPi racecadotril (Hidrasec®, Tiorfan®; benzyl N-[3-(acetylthio)-2-
benzylpropanoyl]glycinate) is approved in Europe and South America for the treatment 
of acute diarrhea. Racecadotril reduces intestinal hyper-secretion of water and 
electrolytes, without affecting basal secretion and has no effect in the normal intestine. 
When given orally, NEP inhibition is solely peripheral; racecadotril does not affect 
central NEP activity. It has a reassuring safety record (>1million adult exposures), with 
rarely reported (<2%) side effects including drowsiness, nausea, dizziness and 
headaches. In adults, single doses of 2g (i.e. 20 times the therapeutic dose for the 
treatment of acute diarrhea), have been administered in clinical trials for up to 3 
months without causing any harmful effects (Lecomte, 2000). Racecadotril has a rapid 
onset of action, with maximal inhibition of NEP at 60 mins following a single dose of 
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100mg (p.o.) in humans (Lecomte, 2000); NEP activity returns to baseline within 8 
hours (the biological half-life is approximately 3.5 hours). This PK profile translates to 
significantly increased plasma ANP levels within 2 h, returning to baseline at 
approximately 6 h (Kahn et al., 1990). Racecadotril does not induce or inhibit CYP450 
enzymes and the principal route of elimination is renal. 
 
Inclusion criteria 
1. WHO Group I pulmonary arterial hypertension (i.e. idiopathic, familial or 
associated with connective tissue diseases) 
2. 18-80 years old 
3. Technically satisfactory RHC (Step 1 only) 
4. Taking sildenafil (20-100 mg; t.i.d.) or tadalafil (20-40mg; o.d.) for at least 
1 month 
5. No changes to any PH-specific therapies for 1 month 
6. Six minute walk distance of >150 m 
7. Not pregnant (women only) 
8. Able to provide consent for the trial 
 
Exclusion criteria 
1. Known sensitivity to racecadotril or its excipients 
2. Clinical diagnosis of liver cirrhosis or ALT/AST >2xULN 
3. Kidney disease with an estimated glomerular filtration rate (eGFR) of 
<50 ml/min 
4. History of angioedema 
5. Systolic blood pressure <85 mmHg 
6. Known history of drug or alcohol abuse within six months of enrolment 
7. Participation in a clinical study involving another investigational drug  
8. Women who are breastfeeding 
9. Taking an angiotensin converting enzyme (ACE) inhibitor 
10. Any clinical condition for which the investigator would consider the 
patient unsuitable for the trial 
 
Biochemical assays 
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 All clinical biochemistry (including NT-proBNP) and hematology analyses were 
conducted at the Royal Free London NHS Foundation Trust. Plasma natriuretic 
peptide, ET-1 and cGMP concentrations were determined using commercially 
available enzyme immunoassay (Phoenix Pharmaceuticals Inc., Karlsruhe, Germany). 
Plasma samples were also analyzed for nitrite (NO2-) and nitrate (NO3-), as an index 
of endogenous NO production (total NOx), using chemiluminescence as described 
previously (Ignarro, Fukuto, Griscavage, Rogers & Byrns, 1993). 
 
Sample size 
Based on previous clinical studies (Berglund, Nyquist, Beermann, Jensen-
Urstad & Theodorsson, 1994; Bruins et al., 2004; Tan, Kloppenborg & Benraad, 1989) 
the between patient standard deviation of the percentage change from baseline in 
ANP (i.e. primary outcome measure) was estimated as 12.2. Sample size calculations 
used a two-sided 5% significance level, 80% power and a 2:1 active:placebo 
randomization ratio. 
 
Step 1 
Within each block of 6 patients (in step 1a and step 1b), a sample size of 4 
patients on active therapy and 2 patients on placebo enabled detection of a difference 
between the two groups in the mean % change in ANP of 50%. Combination of the 
placebo groups from the two blocks of 6 patients, with adjustment for multiple 
comparisons using the Bonferroni procedure, permitted detection of a difference 
between placebo and racecadotril in the mean % change in ANP of 21%. By way of 
precedent, in chronic heart failure 30 mg sinorphan (L-isomer of acetorphan; 
equivalent to 60 mg of racecadotril) increases plasma ANP by 100% (Kahn et al., 
1990) and in cirrhotic patients 100 mg sinorphan elicits a 180% increase in plasma 
ANP (Dussaule et al., 1991). In PH patients, a 21% increase was therefore considered 
conservative. 
 
Step 2 
Using a 2:1 active:placebo ratio, a sample size of 8 patients on active therapy 
and 4 patients on placebo enabled detect of a difference between the two groups in 
the mean % change in ANP of 21%. A 2:1 ratio also provide twice as much 
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information on the safety profile of the drug combination, with minimal effect on the 
difference that would be able to be distinguished. 
 
Early patient safety and biological activity adaptive design 
Step 1 of the study was designed with an adaptive early recruitment phase to 
allow early termination in case of lack of biological activity of racecadotril or harms. 
Step 1 was further broken down into two steps: 
 
Step1a 
After the first 6 patients received a single dose of 100mg of racecadotril or 
placebo, the trial stopped recruitment and key clinical parameters and safety data were 
reviewed in an unblinded fashion by the IDMC who were asked to consider whether a 
dose of racecadotril has been identified that: 
i. on average increases ANP by a minimum of 20% and 
ii. on average decreases PVR by a minimum of 10% and 
iii. on average decreases SBP by no more than 10%. 
based on whether the 95% confidence interval for the relevant (racecadotril – control) 
difference excluded any of these pre-specified clinically important changes. The 
recommendation was to continue recruiting patients without increasing the 
investigational medicinal product (IMP) dose due to the apparent pharmacodynamic 
effect. 
 
Step1b 
An additional 6 patients were recruited into the study and administered a single 
dose of 100mg of racecadotril or placebo followed by the IDMC data review in a similar 
fashion to Step1a. The IDMC recommended proceeding to Step 2 of the trial, recruiting 
patients at the 100mg dose of racecadotril. 
 
Randomization and blinding 
Patients were randomly assigned in a 2:1 ratio to received 100mg of racecadotril 
or matching placebo using random permuted blocks. The allocation sequence was 
computer-generated by the trial statistician and concealment of allocation was ensured 
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by the use of an identical inert placebo, with security in place to ensure allocation of 
unblinded codes could not be accessed by anyone in the trial team other than the 
statistician and the pharmacist (for manufacturing and labeling purposes). 
 
Statistical analyses 
All statistical tests were two-sided with a significance level of 5%. All continuous 
efficacy outcomes were log transformed for the statistical analyses. Results were back 
transformed and are presented as geometric means (GM) and 95% confidence 
intervals (CI), or ratios and 95% CI. All statistical analysis was based on a pre-specified 
Statistical Analysis Plan which was reviewed by the TSC and IDMC. All statistical 
analyses were performed using Stata/IC (Ver.14.2 RRID:SCR_012763; StataCorp, 
College Station, TX, 77845 USA). 
 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data from the 
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are 
permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander 
et al., 2017). 
 
 
RESULTS 
Step 1 
Overview 
 17 patients were screened at the Royal Free London NHS Foundation Trust, 
between February 2014 and December 2015, for entry to Step 1 of the trial. A total of 
15 participants were randomized; Of these, two participants did not receive 
racecadotril (one due to technical difficulties with the RHC and the other was ruled 
unfit to receive IMP) and one participant was withdrawn & replaced (for logistical 
reasons). This is depicted in the CONSORT flow chart (Figure 1). The analysis 
population for Step1 comprises 9 patients allocated to racecadotril and 4 allocated to 
placebo. 
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Characteristics of the study population 
 All baseline and procedural characteristics were similar between groups, 
except the plasma [CNP] which by chance was higher in the placebo group (Table 1). 
The mean age of the trial participants was 57 years, with 77% (10/13) female. All 
participants had significantly raised mPAP (45.54±2.8mmHg) and PVR 
(514.5±39.9dynes/sec/cm-5) consistent with a PAH diagnosis. 
 
Primary endpoint 
 Administration of racecadotril caused an increase in plasma [ANP] that peaked 
at 2 h and returned to baseline by 6 h (Figure 2). This pharmacokinetic profile mirrored 
that observed in previous studies evaluating racecadotril in left heart failure patients 
and closely aligns with the biological half-life of the drug (Dussaule et al., 1991; Kahn 
et al., 1990; Lecomte, 2000). Racecadotril caused a significant increase (79%) in the 
maximum plasma [ANP] whereas a small decrease was observed in the placebo arm 
(albeit two patients receiving placebo exhibited an increase in plasma [ANP]; (Figure 
2). These data suggest that, akin to previous studies in heart failure, NEP inhibition 
causes a significant rise in circulating ANP levels. 
 
Secondary endpoints 
 The increases in plasma [ANP] in patients receiving racecadotril was mirrored 
temporally and in magnitude by plasma cGMP concentrations (Figure 2). Thus, cGMP 
levels peaked at the 2 h timepoint and were 106% higher compared to baseline, 
returning to pre-IMP concentrations after 6 h (Figure 2). Indeed, plasma [cGMP] was 
significantly increased in the racecadotril arm per se and in comparison to placebo 
(Figure 2). These data imply that the temporal elevation in circulating ANP 
concentrations results in a commensurate increase in cGMP formation (via activation 
of GC-A). 
 The parallel rise in plasma levels of ANP and cGMP in response to racecadotril 
exerted a positive influence on pulmonary hemodynamics without having an overt 
effect on the systemic circulation. In this setting, PVR and PCWP were reduced in 
patients receiving racecadotril compared to placebo (although one of four patients in 
the placebo arm also exhibited a reduction in PVR and PCWP), and the peak response 
on pulmonary hemodynamics (2 h) matched the maximum rise in both plasma [ANP] 
and [cGMP] (Figure 3); indeed, there was a significant correlation between increases 
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in plasma [ANP] and plasma [cGMP] with reductions in PVR (Figure 2), tendering 
some elementary indication of causality. A similar trend was observed with mPAP 
(Figure 4) in the absence of any overt change in CO or HR (Table 2). However, there 
was no significant effect of racecadotril on MABP between the active and control arms 
(Figure 4), with MABP falling modestly over time in both groups. 
 Importantly, plasma [ET-1] was not changed following exposure to racecadotril 
(Figure 5). This is a key safety readout since NEP metabolizes a number of vasoactive 
peptides, including ET-1 (Llorens-Cortes, Huang, Vicart, Gasc, Paulin & Corvol, 1992), 
which is known to be a key driver of pathology in PAH and the target of existing therapy 
(Luscher & Barton, 2000; Stewart, Levy, Cernacek & Langleben, 1991; Williamson et 
al., 2000). Additional mechanistic biomarkers were also unaltered following 
racecadotril administration in comparison to placebo. This included plasma 
concentrations of other members of the natriuretic peptide family including BNP (Table 
2), NT-proBNP (Figure 5) and CNP (Table 2), and plasma NOx (as an index of NO 
bioactivity) (Table 2). The lack of effect of NEP inhibition on these biomarkers 
intimates that the rise in plasma [cGMP] and accompanying reductions in PVR and 
PCWP are solely mediated by increased ANP bioactivity. 
 
Safety 
 No serious adverse events (SAE) or serious adverse reactions (SAR) were 
reported in Step 1 of the trial. Only one patient allocated to racecadotril reported (two) 
minor AEs that were potentially drug-related; vomiting and epistaxis. Full details of the 
AEs reported by severity grade, seriousness criteria, causality and trial step can be 
found in Table 5. 
 
Step 2 
Overview 
 A total of 10 patients were screened at the Royal Free London NHS Foundation 
Trust, between May 2016 and October 2016, for possible entry to Step 2 of the trial. 
Of these, 2 were excluded before they were randomized; one patient was unable to 
attend further visits, and a second individual declined to participate after initially 
consenting. Due to logistical difficulties in recruiting patients to this phase of the study 
only 8 participants were randomized; this fell short of the necessary 12 individuals, 
randomized 1:2 to the placebo and racecadotril arms, to be powered to detect a 50% 
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difference in plasma [ANP], the primary endpoint. This is depicted in the CONSORT 
flow chart (Figure 1). The analysis population for Step 2 comprises 5 patients 
allocated to racecadotril and 3 allocated to placebo. 
 
Characteristics of the study population & treatment compliance 
 All baseline and procedural characteristics were similar between groups, 
except by chance the plasma [ANP], plasma [CNP], plasma [cGMP] and plasma [NOx] 
were higher in the placebo group (Table 3). The mean age of the trial participants was 
68 years, with 88% (7/8) female. 
 All patients were treatment compliant; that is, they took at least 30 of the 42 
tablets during the repeat dosage schedule of 12-14 days. The median number of 
capsules taken in the placebo and racecadotril groups was 39 (IQR 39 to 40) and 40 
(IQR 37 to 41), respectively. 
 
Primary endpoint 
 Administration of racecadotril for 14 days caused ~25% increase in plasma 
[ANP], whereas those individuals receiving placebo saw a drop in their plasma [ANP] 
of ~10%; however, an intra-patient analysis did not reveal a significant increase 
(P=0.19), despite an apparent trend (Figure 6). The clear increase in circulating ANP 
levels brought about by NEP inhibition in Step 1 was therefore not maintained to the 
same extent over a period of two weeks in response to t.i.d administration of the same 
dose of racecadotril. 
 
Secondary endpoints 
 Despite the inability to detect an increase in plasma [ANP] following chronic 
dosing, arguably the most important goal of Step 2 was to assess the safety of daily 
use of racecadotril in patients with PH. Administration of racecadotril over 14 days did 
not alter MABP, substantiating the acute lack of effect in Step 1 (Figure 6); moreover, 
chronic administration of racecadotril did not cause any SAEs (see below). 
 Additional mechanistic biomarkers (e.g. cGMP, BNP, NT-proBNP, CNP & NOx) 
were unaltered following racecadotril administration in comparison to placebo (Table 
4). Again, NEP inhibition did not alter plasma [ET-1] levels (Table 4), which is critical 
to any potential therapeutic application of the drug in PAH. 
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Safety 
 No serious adverse events (SAE) or serious adverse reactions (SAR) were 
reported in Step 2 of the trial. Table 5 shows there were a total of 14 minor adverse 
events (AEs) reported by patients allocated to racecadotril, and thought to be 
potentially drug-related, included vomiting, epistaxis, dizziness and headache. The 
difference in the proportion of patients reporting at least one AE between the two arms 
(i.e. 0.33 in the placebo group vs. 0.80 in the racecadotril) was not statistically 
significant (p=0.464; Fisher's exact test). 
 
 
DISCUSSION 
The introduction of PDE5i and sGC stimulators, both of which promote cGMP-
dependent signaling, has significantly improved the treatment of PAH (Galie et al., 
2005; Ghofrani et al., 2013). However, a significant cohort of PAH patients do not 
respond well to these interventions, or experience a diminution of efficacy over time 
(Galie, Manes, Negro, Palazzini, Bacchi-Reggiani & Branzi, 2009). This is particularly 
true of PDE5i since blockade of cGMP breakdown is inexorably dependent on 
endogenous NO and/or natriuretic peptide signaling to drive efficacy (i.e. endogenous 
input to the system), which often wane with disease progression. The development of 
sGC stimulators has negated this decline in efficacy to a certain extent, circumventing 
the reliance on endogenous NO signaling; this is demonstrated, arguably, by 
maintained improvement in 6MWD, WHO functional class and NT-proBNP levels two 
years after initiation of treatment (Rubin et al., 2015). However, pharmacological 
activation of sGC appears not to provide any pulmonary specificity, eliciting a generic 
vasodilator influence which can result in dose-limiting systemic hypotension or drug 
discontinuation for related adverse effects (Galie, Muller, Scalise & Grunig, 2015; 
Ghofrani et al., 2016; Rubin et al., 2015). Thus, identification of drug combinations 
which trigger cGMP signaling preferentially in the pulmonary vasculature and RV have 
potential to optimally harness the therapeutic potential of cGMP above and beyond 
existing therapy, and further improve the treatment of PH. 
 Targeting natriuretic peptide signaling may address this aspiration. Evidence 
from pre-clinical and clinical studies suggests that the therapeutic efficacy of PDE5i in 
PH is primarily dependent on promoting natriuretic peptide bioactivity rather than NO 
(Baliga, Scotton, Trinder, Chambers, MacAllister & Hobbs, 2014; Jin, Yang, Chen, 
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Jackson & Oparil, 1988; Klinger et al., 1993; Louzier et al., 2001; Zhao, Mason, 
Strange, Walker & Wilkins, 2003). This concept provides a clear rationale for 
evaluating combination therapy with PDE5i and NEPi (which slow natriuretic peptide 
inactivation) in PH patients. Indeed, a precedent for such a therapeutic strategy exists 
in left-sided heart failure; the dual NEPi (sacubitril)-angiotensin receptor blocker 
(valsartan), LCZ696, has been demonstrated to reduce mortality and hospitalizations 
by approximately 20% in a large scale RCT (McMurray et al., 2014). 
Herein, acute administration of racecadotril to PH patients stable on PDE5i 
therapy caused a marked augmentation of circulating ANP concentrations that peaked 
at 2h and returned to baseline within 6h. This pharmacodynamic profile closely 
matches the plasma half-life of the drug (6-8 h). The circulating levels of cGMP 
followed an almost identical time-course and magnitude. These commensurate 
increases provide good evidence of the anticipated efficacy of NEPi in the PAH 
patients population, increasing ANP/GC-A/cGMP signaling for therapeutic gain. 
Accordingly, acute administration of racecadotril produced a commensurate effect on 
pulmonary hemodynamics (i.e. PVR and PCWP), but not the systemic vasculature, as 
predicted by pre-clinical models (a phenomenon also observed following 
administration of NEPi to healthy volunteers (Ando, Rahman, Butler, Senn & Floras, 
1995)). The time-course of reduction in pulmonary hemodynamic variables also 
matched the biological half-life of the drug and the temporal profile of the enhancement 
of ANP and cGMP. Yet, there was little or no effect on MABP across the entire time-
course of the acute study, which was corroborated by observations from the 14 day 
evaluation in which systemic hemodynamics remained unchanged between the 
placebo and active arms. These findings give credence to thesis that combination of 
PDE5i and NEPi produces a pulmonary-specific effect on hemodynamics. 
Importantly, administration of racecadotril was not associated with an overt 
increase in circulating ET-1 concentrations. This is an important finding since NEP is 
thought to underpin a principle route of ET-1 breakdown & inactivation (Llorens-
Cortes, Huang, Vicart, Gasc, Paulin & Corvol, 1992). ET-1 is well-established to 
contribute to disease progression in PH and pharmacological blockade of its cognate 
receptor(s), particularly the ETA subtype, is effective in treating the disease (Luscher 
& Barton, 2000; Stewart, Levy, Cernacek & Langleben, 1991; Williamson et al., 2000). 
Thus, at least in this relatively short-term evaluation, the efficacy of NEP inhibition 
does not appear to be limited by detrimental augmentation of ET-1 bioactivity. 
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Interestingly, the plasma concentrations of BNP and NT-proBNP did not show a similar 
significant change in patients receiving racecadotril, which likely reflects the reduced 
susceptibility of BNP to breakdown by NEP (compared to ANP; (Watanabe, Nakajima, 
Shimamori & Fujimoto, 1997). CNP levels were also unaltered in the face of NEP 
blockade; this is perhaps surprising since this is the preferred natriuretic peptide 
substrate for NEP (Watanabe, Nakajima, Shimamori & Fujimoto, 1997). However, 
CNP acts primarily in a paracrine fashion, and its systemic concentrations might not 
reflect tissue levels(Potter, 2011). Finally, and as expected, the circulating NOX 
concentrations were not altered by NEP inhibition, confirming that the increases in 
cGMP observed in patients receiving racecadotril were exclusively due to upregulation 
of ANP/GC-A signaling, and not through activation of NO–driven pathways. 
Longer term (14 day) treatment with racecadotril did not appear to give rise to 
equivalent increases in circulating ANP levels as achieved by acute administration. 
This reduced efficacy is likely underpinned by two explanations. First, the study was 
powered to detect an intra-patient difference in plasma [ANP] of 21%, so since 
recruitment fell short of the desired total in Step 2 a larger prospective study would be 
required to corroborate a beneficial effect of this magnitude. Second, the rapid 
pharmacokinetic and pharmacodynamic profile of racecadotril with respect to plasma 
[ANP] demonstrated in Step 1 implies that time of administration is critical to detection 
of elevated levels. Whilst patients were requested to take their final dose of 
racecadotril on the morning of their 14 day assessment (concurrently with their PDE5i 
therapy), the time between consumption and hospital evaluation varied greatly and did 
not coincide with the peak plasma [ANP] identified in Step 1. However, previous 
clinical studies in heart failure have demonstrated that NEP inhibition (using ecadotril, 
omapatrilat or LCZ696) maintains elevated [ANP] and/or [cGMP] chronically, for up to 
eight months (Campese et al., 2001; Cleland & Swedberg, 1998; McMurray et al., 
2014; Packer et al., 2015), tendering reassurance that NEPi are likely to exert a similar 
longer-term pharmacological action in the PH patient cohort. Additionally, this trial did 
not investigate the dose-response relationship for racecadotril in PAH patients, rather 
the study utilized the licensed dose of this NEPi for safety and repurposing intentions. 
Thus, it is possible that the maximum pharmacodynamic effect has not been reached 
and higher concentrations of racecadotril would exert greater beneficial activity. 
Further optimization in this context is warranted. Regardless, it should be noted that 
the fall in PVR produced by NEP inhibition herein was on top of that provided by 
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existing PDE5i therapy, suggesting current cGMP-centric drugs can be further 
enhanced. 
 With respect to safety, racecadotril has a reassuring profile with more than 1 
million patient exposures without overt evidence of serious side effects. Whilst there 
were numerically more adverse events reported by patients taking racecadotril versus 
placebo, there was not a statistical difference between the two groups; moreover, the 
adverse events reported by those taking racecadotril were mild and largely expected 
based on the vascular (vasodilator) and intestinal (diminution of Cl- & water secretion) 
effects of NEP inhibition, including headache, dizziness & constipation. These 
observations give reassurance that chronic use of NEPi in the PAH population will be 
well-tolerated and safe, although a longer-term study will be needed to ratify this. 
 In sum, this study provides proof-of-concept clinical evidence of the therapeutic 
potential of repurposing NEP inhibition in PAH. The beneficial effects of NEPi are 
dependent on endogenous natriuretic peptide bioactivity, synergize with PDE5i, and 
exhibit a pulmonary-specific action. The dual mechanism of action inherent to a 
PDE5i/NEPi combination is unique in terms of existing PH therapy (which target one 
step in the cGMP signaling cascade) and therefore holds a theoretical advantage in 
treating the disease. These findings warrant a larger-scale, prospective study with this 
combination therapy in PH patients to determine if efficacy, selectivity and safety are 
maintained over a longer period with respect to pulmonary hemodynamics, RV 
function, exercise capacity, and quality of life. 
 
 
FUNDING 
This work was supported by a British Heart Foundation Project Grant 
(PG/11/88/28992) and the National Institutes for Health Research, Comprehensive 
Biomedical Research Centre award to UCL. 
 
 
ACKNOWLEDGEMENTS 
 The authors would like to acknowledge the contribution made by the members 
of the trial steering committee and independent data monitoring committee, Prof. 
Martin Wilkins, Prof. Mark Griffiths & Dr. Timothy Collier. 
 
20 
 
CONFLICT OF INTEREST 
BS has been a consultant/advisory board member for GSK & Actelion. JC has 
been a consultant/advisory board member for Actelion, GSK, Bayer, United 
Therapeutics, Endotronic & Pfizer. AH has been a consultant/advisory board member 
for Bayer AG, Serodus ASA & Palatin Technologies Inc. 
 
 
AUTHOR CONTRIBUTIONS 
All authors made a significant contribution to the experimental design, data 
acquisition and analysis/interpretation, were involved with drafting or critically 
appraising the manuscript, gave approval for submission, and are familiar with all 
aspects of the study. 
 
 
DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR 
This Declaration acknowledges that this paper adheres to the principles for 
transparent reporting and scientific rigour of preclinical research as stated in the BJP 
guidelines for Design & Analysis, and as recommended by funding agencies, 
publishers and other organisations engaged with supporting research. 
  
21 
FIGURES 
 
Figure 1. CONSORT flow chart for Step 1 (left panel) and Step 2 (right panel) 
 
Figure 2. Time course (left panel), absolute change (middle panels), and maximum 
percentage change from baseline (right panel) in plasma atrial natriuretic peptide 
concentration ([ANP]; A) or cyclic guanosine-3’,5’-monophosphate concentration 
([cGMP]; B) in PAH patients receiving racecadotril (100mg) or matching placebo. Data 
are represented as geometric mean ± 95% CI. n=4 (placebo) and n=9 (racecadotril). 
Data were analyzed by paired t-test for absolute intra-patient change (i.e. before and 
after treatment) and by unpaired t-test for inter-group comparison (i.e. placebo v 
racecadotril) of Δmax (%). Correlation between maximum percentage change in PVR 
and maximum percentage change in plasma [ANP] or plasma [cGMP] (C). n=4 
(placebo) and n=8 (racecadotril). Data were analyzed by Pearson correlation. In all 
cases P<0.05 was considered statistically significant. 
 
Figure 3. Time course (left panel), absolute change (middle panels), and maximum 
percentage change from baseline (right panel) in pulmonary vascular resistance (PVR; 
A) or pulmonary capillary wedge pressure (PCWP; B) in PAH patients receiving 
racecadotril (100mg) or matching placebo. Data are represented as geometric mean 
± 95% CI. n=4 (placebo) and n=8 (racecadotril). Data were analyzed by paired t-test 
for absolute intra-patient change (i.e. before and after treatment) and by unpaired t-
test for inter-group comparison (i.e. placebo v racecadotril) of Δmax (%). P<0.05 was 
considered statistically significant. 
 
Figure 4. Time course (left panel), absolute change (middle panels), and maximum 
percentage change from baseline (right panel) in mean pulmonary artery pressure 
(mPAP; A) or mean arterial blood pressure (MABP; B) in PAH patients receiving 
racecadotril (100mg) or matching placebo. Data are represented as geometric mean 
± 95% CI. n=4 (placebo) and n=9 (racecadotril). Data were analyzed by paired t-test 
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for absolute intra-patient change (i.e. before and after treatment) and by unpaired t-
test for inter-group comparison (i.e. placebo v racecadotril) of Δmax (%). P<0.05 was 
considered statistically significant. 
 
Figure 5. Time course (left panel), absolute change (middle panels), and maximum 
percentage change from baseline (right panel) in plasma endothelin-1 concentration 
([ET-1]; A) or N-terminal-pro-brain natriuretic peptide concentration ([NT-proBNP]; B) 
in PAH patients receiving racecadotril (100mg) or matching placebo. Data are 
represented as geometric mean ± 95% CI. n=4 (placebo) and n=9 (racecadotril). Data 
were analyzed by paired t-test for absolute intra-patient change (i.e. before and after 
treatment) and by unpaired t-test for inter-group comparison (i.e. placebo v 
racecadotril) of Δmax (%). P<0.05 was considered statistically significant. 
 
Figure 6. Absolute change (left & middle panels) and maximum percentage change 
from baseline (right panel) in mean arterial blood pressure (MABP; A) or plasma atrial 
natriuretic peptide concentration ([ANP]; B) in PAH patients receiving racecadotril 
(100mg; tid; 14 days) or matching placebo. Data are represented as geometric mean 
± 95% CI. n=3 (placebo) and n=5 (racecadotril). Data were analyzed by paired t-test 
for absolute intra-patient change (i.e. before and after treatment) and by unpaired t-
test for inter-group comparison (i.e. placebo v racecadotril) of Δmax (%). P<0.05 was 
considered statistically significant. 
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Table 1. Baseline characteristics of study population – Step 1 
Characteristic  Placebo (n=4) Racecadotril (n=9) 
Demographics    
Age (years) Mean (SD) 58 (10) 57 (14) 
Sex (M/F) 0/4 3/6 
Ethnicity    
Caucasian Number (%) 4 (100) 8 (89) 
Black African Number (%) 0 (0) 1 (11) 
Weight (kg) Mean (SD) 72.5 (24.3) 76.8 (8.3) 
Height (m) Mean (SD) 1.65 (0.06) 1.70 (0.14) 
Body Mass Index (kg/m2) Mean (SD) 28.3 (7.7) 26.9 (4.7) 
Clinical biochemistry    
ALT (U/L) GM (95% CI) 16 (12 to 21) 19 (15 to 24) 
AST (U/L) GM (95% CI) 18 (12 to 27) 23 (19 to 28) 
eGFR (mL/min) GM (95% CI) 63 (50 to 79) 72 (62 to 82) 
Hb (g/L) GM (95% CI) 137 (120 to 156) 129 (113 to 146) 
WBC (x109/L) GM (95% CI) 8 (4 to 15) 7 (6 to 8) 
RBC (x1012/L) GM (95% CI) 4.62 (4.20 to 5.08) 4.33 (3.87 to 4.83) 
PT (s) GM (95% CI) 11 (10 to 13) 16 (12 to 23) 
APTT (s) GM (95% CI) 30 (27 to 33) 36 (33 to 39) 
Disease characteristics    
Time since diagnosis (months) Mean (SD) 11.3 (0.6 to 198.9) 24.3 (12.1 to 48.8) 
PH Group    
1.1 Idiopathic Number (%) 1 (25) 3 (33) 
1.4.1 CTD Number (%) 2 (75) 6 (67) 
1.4.4 CHD Number (%) 1 (25) 0 (0) 
WHO Functional Class    
I Number (%) 0 (0) 2 (22) 
II Number (%) 2 (50) 1 (11) 
III Number (%) 2 (50) 6 (67) 
6MWD (m) GM (95% CI) 364 (198 to 669) 402 (335 to 483) 
Borg dyspnea score Mean (SD) 11.8 (3.2) 10.8 (3.9) 
Concurrent PH therapy    
Sildenafil Number (%) 4 (100) 10 (89) 
Tadalafil Number (%) 0 (0) 1 (11) 
ERA Number (%) 1 (25) 8 (89) 
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Prostacyclin analogue Number (%) 0 (0) 1 (11) 
Diuretic Number (%) 1 (25) 6 (67) 
Primary endpoint    
Plasma [ANP] (nM) GM (95% CI) 0.11 (0.06 to 0.20) 0.08 (0.05 to 0.12) 
Systemic haemodynamics    
MABP (mmHg) GM (95% CI) 95 (79 to 115) 89 (81 to 98) 
SBP (mmHg)  GM (95% CI) 133 (111 to 159) 122 (112 to 133) 
DBP (mmHg)  GM (95% CI) 76 (60 to 95) 72 (64 to 81) 
SaO2 (%) GM (95% CI) 94 (89 to 100) 95 (93 to 98) 
Pulmonary haemodynamics    
mPAP (mmHg) GM (95% CI) 48 (37 to 62) 43 (36 to 51) 
PVR (dynes/sec/cm-5) GM (95% CI) 549 (327 to 921) 470 (368 to 602) 
PCWP (mmHg) GM (95% CI) 10 (6 to 19) 11 (10 to 13) 
TAPSE (mm) GM (95% CI) 22.6 (19.5 to 26.1) 19.0 (15.7 to 22.9) 
TRV (m/s) GM (95% CI) 4.1 (2.4 to 6.8) 3.2 (2.8 to 3.8) 
Cardiac indices    
HR (bpm) GM (95% CI) 85 (63 to 116) 72 (64 to 80) 
CO (L/min)  GM (95% CI) 5.4 (2.9 to 10.3) 5.4 (4.3 to 6.7) 
SV (mL) GM (95% CI) 64 (42 to 97) 75 (59 to 95) 
LVEF (%) GM (95% CI) 57 (53 to 61) 56 (55 to 58) 
LA area (cm2) GM (95% CI) 15.6 (11.7 to 20.7) 18.2 (15.2 to 21.9) 
RA area (cm2) GM (95% CI) 19.1 (13.3 to 27.5) 19.7 (15.0 to 25.8) 
RV diameter (cm) GM (95% CI) 3.9 (3.0 to 5.2) 3.7 (3.3 to 4.2) 
Pericardial effusion Number (%) 0 (0) 2 (22) 
Biomarkers    
Plasma [BNP] (nM) GM (95% CI) 0.007 (0.00002 to 2.01) 0.004 (0.0004 to 0.04) 
Plasma [NT-proBNP] (nM) GM (95% CI) 38 (10 to 137) 40 (18 to 89) 
Plasma [CNP] (pM) GM (95% CI) 706 (0 to 1642008) 38 (1 to 2214) 
Plasma [cGMP] (nM) GM (95% CI) 41 (14 to 119) 17 (8 to 36) 
Plasma [ET-1] (nM) GM (95% CI) 1.96 (1.14 to 3.36) 1.86 (1.62 to 2.14) 
Plasma [NOx] (nM) GM (95% CI) 36274 (14389 to 91445) 31642 (15836 to 63223) 
SD=Standard Deviation, GM=Geometric Mean, ALT=Alanine transaminase, AST=Aspartate transaminase, eGFR=estimated glomerular filtration rate, Hb=haemoglobin, WBC=white blood cell count, RBC=red blood cell count, PT=Prothrombin time, APTT=activated partial thromboplastin time, CTD=connective tissue disease, CHD=congenital heart disease, 6MWD=6 minute walk distance, ERA=endothelin receptor antagonist, mPAP=mean pulmonary artery pressure, PVR=pulmonary vascular resistance, PCWP=pulmonary capillary wedge pressure, TAPSE=Tricuspid annular plane systolic excursion, TRV=Tricuspid regurgitant velocity, HR=heart rate, CO=cardiac output, SV=stroke volume, LVEF=Left ventricular ejection fraction, LA=Left atrium, RA=right atrium, RV=Right ventricle, BNP=Brain natriuretic peptide, NT-proBNP=N-terminal-proBNP, CNP=C-type natriuretic peptide, cGMP=cyclic guanosine-3’,5’-monophosphate, ET-1=Endothelin-1, NOx=[NO2-]+[NO3-] 
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Table 2. Additional hemodynamic and biomarker parameters– Step 1 
Characteristic Placebo (n=4) Racecadotril (n=9) P-value 
Systemic hemodynamics    
ΔSBP (mmHg)  -6 (-54 to 94) -15 (-25 to -3) 0.18 
0.44 
0.64 
0.56 
0.56 
ΔDBP (mmHg)  -16 (-60 to 74) -24 (-37 to -9) 
ΔHR (bpm) -22 (-36 to -6) -4 (-24 to 21) 
ΔCO (L/min) 0.2 (-0.3 to 0.6) 0.3 (-0.1 to 0.6) 
ΔSV (mL) 29 (6 to 58) 33 (20 to 46) 
ΔSaO2 (%) -1 (-12 to 12) -1 (-6 to 3) 0.99 
Biomarkers    
ΔPlasma [BNP] (nM) 155 (-84 to 4367) 32 (-79 to 714) 0.37 
0.36 
0.56 
ΔPlasma [CNP] (pM) -1 (-96 to 2466) -44 (-87 to 154) 
ΔPlasma [NOx] (nM) -28 (-49 to 0) -47 (-77 to 22) 
Data are presented as change in Geometric Mean (95% CI)  
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Table 3. Baseline characteristics of study population – Step 2 
Characteristics  Placebo 
(n=3) 
Racecadotril 
(n=5) 
Demographics    
Age (years) Mean (SD) 67 (3) 69 (7) 
Sex (M/F) 1/2 0/5 
Ethnicity    
Caucasian Number (%) 3 (100) 4 (80) 
Black African Number (%) 0 (0) 1 (20) 
Weight (kg) Mean (SD) 77.0 (20.3) 77.0 (20.3) 
Height (m) Mean (SD) 1.67 (0.07) 1.63 (0.07) 
Body Mass Index (kg/m2) Mean (SD) 27.5 (6.1) 29.3 (7.8) 
Clinical biochemistry    
ALT (U/L) GM (95% CI) 19 (13 to 26) 24 (11 to 53) 
AST (U/L) GM (95% CI) 21 (14 to 31) 23 (11 to 46) 
eGFR (mL/min) Median (IQR) 69 (71 to 90) 73 (73 to 90) 
Hb (g/L) GM (95% CI) 120 (76 to 188) 127 (114 to 142) 
WBC (x109/L) GM (95% CI) 6 (4 to 11) 5 (4 to 6) 
RBC (x1012/L) GM (95% CI) 4.26 (3.02 to 5.99) 4.51 (3.76 to 5.42) 
PT (s) GM (95% CI) 11 (11 to 13) 17 (9 to 31) 
APTT (s) GM (95% CI) 36 (25 to 52) 37 (31 to 44) 
Disease characteristics    
Time since diagnosis (months) Mean (SD) 35.0 (27.8) 13.4 (11.2) 
PH Group    
1.1 Idiopathic Number (%) 0 (0) 1 (20) 
1.4.1 CTD Number (%) 3 (100) 4 (80) 
1.4.4 CHD Number (%) 0 (0) 0 (0) 
WHO Functional Class    
I Number (%) 1 (33) 0 (0) 
II Number (%) 0 (0) 2 (40) 
III Number (%) 2 (67) 3 (60) 
6MWD (m) GM (95% CI) 443 (201 to 975) 315 (191 to 522) 
Borg dyspnea score Mean (SD) 10.7 (3.2) 13.0 (3.7) 
Concurrent PH therapy    
Sildenafil Number (%) 3 (100) 5 (100) 
Tadalafil Number (%) 0 (0) 0 (0) 
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ERA Number (%) 0 (0) 2 (40) 
Prostacyclin analogue Number (%) 0 (0) 0 (0) 
Diuretic Number (%) 3 (100) 3 (60) 
Primary endpoint    
Plasma [ANP] (nM) GM (95% CI) 0.20 (0.17 to 0.24) 0.16 (0.08 to 0.34) 
Systemic hemodynamics    
MABP (mmHg) GM (95% CI) 73 (34 to 156) 70 (55 to 90) 
SBP (mmHg)  GM (95% CI) 115 (78 to 170) 121 (105 to 141) 
DBP (mmHg)  GM (95% CI) 71 (46 to 111) 68 (54 to 86) 
SaO2 (%) GM (95% CI) 97 (91 to 103) 95 (93 to 97) 
Pulmonary haemodynamics    
TAPSE (mm) GM (95% CI) 23.7 (14.0 to 40.0) 17.6 (10.6 to 29.0) 
TRV (m/s) GM (95% CI) 2.61 (0.69 to 9.93) 3.62 (2.84 to 4.61) 
Cardiac indices    
HR (bpm) GM (95%CI) 87 (48 to 158) 88 (72 to 107) 
CO (L/min)  GM (95% CI) 5.4 (2.9 to 10.3) 5.4 (4.3 to 6.7) 
SV (mL) GM (95% CI) 64 (42 to 97) 75 (59 to 95) 
LVEF (%) GM (95% CI) 58 (58 to 58) 57 (54 to 60) 
LA area (cm2) GM (95% CI) 22.6 (19.1 to 26.8) 19.1 (11.7 to 31.3) 
RA area (cm2) GM (95% CI) 24.3 (19.3 to 30.5) 18.0 (13.4 to 24.1) 
RV diameter (cm) GM (95% CI) 3.7 (2.8 to 5.0) 3.8 (3.2 to 4.5) 
Pericardial effusion Number (%) 1 (33) 1 (20) 
SD=Standard Deviation, GM=Geometric Mean, IQR=Interquartile Range, ALT=Alanine transaminase, AST=Aspartate transaminase, eGFR=estimated glomerular filtration rate, Hb=haemoglobin, WBC=white blood cell count, RBC=red blood cell count, PT=Prothrombin time, APTT=activated partial thromboplastin time, CTD=connective tissue disease, CHD=congenital heart disease, 6MWD=6 minute walk distance, ERA=endothelin receptor antagonist, mPAP=mean pulmonary artery pressure, PVR=pulmonary vascular resistance, PCWP=pulmonary capillary wedge pressure, TAPSE=Tricuspid annular plane systolic excursion, TRV=Tricuspid regurgitant velocity, HR=heart rate, CO=cardiac output, SV=stroke volume, LVEF=Left ventricular ejection fraction, LA=Left atrium, RA=right atrium, RV=Right ventricle, BNP=Brain natriuretic peptide, NT-proBNP=N-terminal-proBNP, CNP=C-type natriuretic peptide, cGMP=cyclic guanosine-3’,5’-monophosphate, ET-1=Endothelin-1, NOx=[NO2-]+[NO3-]   
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Table 4. Additional hemodynamic and biomarker parameters– Step 2 
Characteristic Placebo 
(n=3) 
Racecadotril  
(n=5) P-value 
Hemodynamics    
ΔSBP (mmHg)  -10 (-42 to 41) -4 (-24 to 19) 0.36 
ΔDBP (mmHg)  -10 (-56 to 83) -4 (-19 to 13) 0.70 
ΔHR (bpm) -7 (-38 to 40) 24 (5 to 46) 0.05 
ΔSaO2 (%) 0 (-7 to 6) 0 (-3 to 3) 0.97 
Biomarkers    
ΔPlasma [BNP] (nM) 548 (-100 to 1195000) -66 (-99 to 1336) 0.20 
ΔPlasma [NT-proBNP] (nM) 16 (-75 to 440) -12 (-20 to -3) 0.40 
ΔPlasma [CNP] (pM) -16 (-44 to 26) -2 (-16 to 16) 0.16 
ΔPlasma [cGMP] (nM) -51 (-92 to 193) 34 (-64 to 395) 0.66 
ΔPlasma [ET-1] (nM) -21 (-84 to 278) -20 (-37 to 1) 0.96 
ΔPlasma [NOx] (nM) -23 (-79 to 186) 1 (-48 to 94) 0.96 
Data are presented as change in Geometric Mean (95% CI) 
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Table 5. Adverse events by severity, seriousness and causality for each trial step 
Trial 
step Patient ID 
Treatment 
group Adverse event 
Severity 
grade 
(0-5) 
Seriousness Outcome Treatment related? 
1 COM202 Racecadotril Vomiting 2 Not serious Resolved Possibly 
1 COM202 Racecadotril Epistaxis 2 Not serious Resolved Possibly 
2 COM121 Racecadotril Headache 1 Not serious Resolved Possibly 
2 COM121 Racecadotril Diarrhoea 1 Not serious Resolved No 
2 COM121 Racecadotril Dizziness 1 Not serious Resolved Possibly 
2 COM121 Racecadotril Cough 1 Not serious Resolved Possibly 
2 COM121 Racecadotril Vomiting 1 Not serious Resolved Possibly 
2 COM123 Racecadotril Headache 1 Not serious Resolved Possibly 
2 COM123 Racecadotril Epistaxis 1 Not serious Resolved Possibly 
2 COM123 Racecadotril Stomach pain 1 Not serious Resolved Possibly 
2 COM123 Racecadotril 
Upper 
respiratory tract 
infection 
2 Not serious Resolved Possibly 
2 COM125 Racecadotril Constipation 1 Not serious Resolved Possibly 
2 COM126 Placebo Diarrhoea 2 Not serious Resolved No 
2 COM126 Placebo Dry skin 1 Not serious Resolved No 
2 COM127 Racecadotril Hiccups 1 Not serious Resolved No 
2 COM127 Racecadotril Body cramps 1 Not serious Resolved No 
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